Next Article in Journal
Inspiring Anti-Tick Vaccine Research, Development and Deployment in Tropical Africa for the Control of Cattle Ticks: Review and Insights
Next Article in Special Issue
Bacterial Pathogenesis in Various Fish Diseases: Recent Advances and Specific Challenges in Vaccine Development
Previous Article in Journal
Monkeypox Cross-Sectional Survey of Knowledge, Attitudes, Practices, and Willingness to Vaccinate among University Students in Pakistan
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Strategies for Prevention and Control of Vibriosis in Asian Fish Culture

1
Fisheries College, Key Laboratory of Healthy Mariculture for the East China Sea, Ministry of Agriculture, Jimei University, Xiamen 361021, China
2
Institute of Electromagnetics and Acoustics, School of Electronic Science and Engineering, Xiamen University, Xiamen 361005, China
3
Fisheries College, Fujian Engineering Research Center of Aquatic Breeding and Healthy Aquaculture, Jimei University, Xiamen 361021, China
*
Authors to whom correspondence should be addressed.
second corresponding author.
first corresponding author.
Vaccines 2023, 11(1), 98; https://doi.org/10.3390/vaccines11010098
Submission received: 16 November 2022 / Revised: 26 December 2022 / Accepted: 27 December 2022 / Published: 31 December 2022
(This article belongs to the Special Issue Aquaculture Diseases: Prevention and Control Strategies)

Abstract

:
It is estimated that vibriosis account for about half of the economic losses in Asian fish culture. Consequently, the prevention and control of vibriosis is one of the priority research topics in the field of Asian fish culture disease. Relevant measures have been proposed to control some Vibrios that pose a threat to Asian fish culture, but there are currently only a few effective vaccines available to combat these Vibrios. The purpose of our review is to sum up the main prevention methods and the latest control strategies of seven Vibrio species that cause great harm to Asian aquaculture, including Vibrio harveyi, Vibrio vulnificus, Vibrio parahaemolyticus, Vibrio mimicus, Vibrio anguillarum, Vibrio alginolyticus and Vibrio cholerae. Strategies such as antibiotics, probiotics, bacteriophages, antimicrobials from plants and other natural sources, as well as vaccines, are compared and discussed here. We expect this review will provide some new views and recommendations for the future better prevention and control of vibriosis in Asian fish culture.

1. Introduction

Twenty years ago, aquatic products played a secondary role in people’s food choices. However, now aquatic products have become one of the mainstream food categories. Looking back on the development of global aquaculture from 1997 to 2017, aquaculture has made a substantial contribution to food production throughout the world, especially in Asia. According to the current consumption, aquaculture production needs to increase from 82,087 kilotons in 2018 to 129,000 kilotons in 2050 to meet global needs [1,2]. By 2050, aquaculture will dominate the global seafood supply [3].
Vibrio is one of the important pathogenic microorganisms of humans and marine animals. It widely exists in marine and freshwater ecosystems. Because of its high abundance and biomass, Vibrio plays a crucial role in the aquatic environment. More than 80 species of Vibrio have been reported, some of which are pathogenic to animals, especially aquatic animals, some to humans, and some to both animals and humans [4]. The outbreak of vibriosis will not only seriously affect marine biomass but also lead to serious economic losses in Asian fish culture.
With the rapid development of Asian fish culture in recent decades, the cases of Vibrio infection through aquatic products at home and abroad, causing human disease or huge economic losses, are also increasing year by year. At the same time, the prevention and control measures for Vibrio are also developing. At present, the use of antibiotics is the most important treatment for vibriosis in Asian fish culture [5]. At the same time, the overuse of broad-spectrum antibiotics has resulted in an increase in the number of drug-resistant bacteria. The resistance genes of these bacteria can be transferred to other bacteria that have never been exposed to the antibiotic [6]. Therefore, it is necessary to develop some antibiotic-free methods. For example, using vaccines, probiotics, bacteriophages and other technologies.
Before considering the prevention and control of Vibrio, it is essential first to identify the exact pathogen. At present, the mainly used identification methods are still conventional physiological, biochemical analyses, 16S rDNA sequencing and drug sensitivity test. In addition to these widely used assays, some convenient, fast and highly sensitive detection methods have been developed in recent years, for example, the identification of biomarkers based on host genes [7], exosomic miRNAs [8] and so on.
Vaccination in Asian fish culture can prevent or mitigate the spread of disease and is effective against many related pathogens [9]. Vaccination is usually a secure and economic precaution. For this reason, illness prevention based on stimulating the immune system of aquatic animals has proved to be the basis of the development of modern Asian fish culture. Nevertheless, there are only a few Vibrios with vaccine control technology.
This review discusses the control and prevention strategies of seven Vibrio species that are seriously harmful to Asian fish culture, including Vibrio harveyi, Vibrio vulnificus, Vibrio parahaemolyticus, Vibrio mimicus, Vibrio anguillarum, Vibrio alginolyticus and Vibrio cholerae. For each Vibrio, we describe their prevention and treatment methods (Figure 1), especially vaccine prevention methods, in order to provide views for better prevention and control of vibriosis in Asian fish culture in the future.

2. Control and Prevention Strategies of Vibrios

2.1. V. harveyi

V. harveyi is a luminous marine bacterium and is also a well-recognized and acute pathogen of marine fish [10]. The research on the control and prevention measures of V. harveyi started early, and now there are a variety of control technologies (Table 1).

2.1.1. Antibiotics

Antibiotic methods are generally used in the initial stage of prevention and treatment of vibriosis or emergency treatment. In the case of skin ulcer disease of young hybrid groupers, researchers confirm that the pathogen of this sickness is V. harveyi ML01 strain, which is sensitive to minocycline, doxycycline and ceftriaxone. In other words, these three antibiotics can be used for emergency treatment of V. harveyi infection [11]. In 2017, the drug sensitivity test of V. harveyi extracted from the diseased cultured hippocampus was carried out, and the results showed that V. harveyi is highly sensitive to doxycycline and tetracycline. This provides a reference for the prevention strategy of vibriosis in seahorse culture in eastern China [12]. Although antibiotics are widely used, the rapid increase in antibiotic resistance is really puzzling.

2.1.2. Bacteriophages

As people gradually realize the risk of using antibiotics in Asian fish culture, probiotics, bacteriophage, antimicrobials from natural sources and so on are gradually replacing antibiotics. In bacteriophage therapy, phages such as lytic Vibrio phage VhKM4 [13] can resist V. harveyi efficiently due to its strong lytic activity. Although several research studies have proven these methods effective, there have not been enough similar studies of each method to prove that they should be promoted in practical application. At the same time, whether these biological control methods have potential threats still needs further study in future research.

2.1.3. Vaccines

One of the research hot spots of Vibrio prevention is vaccine development. Most research on V. harveyi vaccine is targeted at fish. Many excellent achievements have been made in the research of V. harveyi vaccine. Vaccine exploration started from the traditional whole-cell inactivation method, followed by the study on the method of purifying subcellular components, making vaccine technology enter the era of modern vaccines represented by DNA vaccine [10].
Whole-cell vaccines can be categorized into two types, attenuated live vaccine and inactivated vaccine. The production cost of these vaccines is not high [14]. This traditional vaccine is the most widely used in the prevention of aquatic animal diseases.
  • Inactivated vaccines
FKVh, a vaccine mainly composed of formalin-inactivated V. harveyi Vh1 strain, may be an effective vaccine, and the survival rate of hybrid tilapia increased from 20% to 87% after vaccination [15]. There is also a combined vaccine (VICV) against V. vulnificus, V. alginolyticus, V. harveyi and infectious spleen and kidney necrosis virus (ISKNV). Huang et al. have proved its immunization effectiveness by immunizing orange-spotted grouper Epinephelus coioides with the VICV vaccine and attacking the above four pathogens [16]. Compared with the monovalent vaccine, this kind of vaccine can more conveniently protect fish from a variety of pathogens.
Although the production cost of inactivated vaccines is relatively lower compared with other kinds of vaccines, their performance still needs to be continuously improved. This can be achieved by combining adjuvants, liposome embedding and other methods. Research has proposed a greatly effective vaccine that can prevent V. harveyi. The vaccine consists of inactivated V. harveyi cells and ISA763 AVG adjuvant. The experiment observed that the RPS of grouper inoculated with this vaccine was 100% in the sixth week and 91.7% in the twelfth week after being attacked by V. harveyi [17]. The formalin-inactivated cell of V. harveyi adjuvanted with Montanide TMISA 763 AVG induced efficient immune protection in turbot [18]. Similarly, the application of liposomes-entrapped V. harveyi WCV or V. harveyi WC can actively strengthen the immune system and provide protection for V. harveyi infection in Epinephelus bruneus [19]. The expression standard of various immune substances in the grouper‘s spleen is significantly up-regulated after inoculation in the laboratory, using a vaccine made of inactivated V. harveyi ZJ0603 combined with β-glucan [20].
  • Attenuated live vaccines
An attenuated live vaccine has been developed to highly protect Japanese flounder (Paralichthys olivaceus) infected with V. harveyi in the experiment. The vaccine is made of live Escherichia coli, which can express and secrete Vhp1 with impaired cytotoxicity [21]. Moreover, a study shows that V. harveyi WC13DH51 strain can be made into a live attenuated vaccine and has a significant protective effect on groupers [22]. Furthermore, an attenuated live vaccine was developed by constructing recombinant Et15VhD. The infection experiment shows that this vaccine can effectively prevent the infection of V. harveyi and E. tarda [23]. Similarly, the attenuated mutant strain T4DM of V. harveyi can also be used as a live attenuated vaccine. On the medium containing rifampicin with increased concentration, T4DM was obtained by selecting T4D mutants repeatedly with a relatively narrow antibiotic resistance profile and no detectable plasmid. T4DM is also a cross-protection vaccine, which can effectively protect Japanese flounder from the infection of V. alginolyticusvia and V. harveyi, especially through immersion (108 CFU/mL) and intraperitoneal injection (108 CFU/mL) [24].
  • Subunit vaccines
A subunit vaccine made of purified recombinant Vhp1 can effectively render Japanese flounder V. harveyi-resistant [21]. There is also a V. harveyi subunit vaccine encoding TssJ antigen that was found to emerge a moderate protective role against V. harveyi in fish. The full-length sequence of TssJ was obtained from the V. harveyi strain QT520 and was predicted as a new candidate antigen, whose relative percentage survival was 52.39% [25]. Moreover, based on VirB11, a recombinant protein vaccine was developed and became a candidate vaccine to prevent V. harveyi infection [26]. In addition, recombinant cell vaccines expressing the DnaJ and OmpK have strong cross-protection against V. alginolyticus, V. parahaemolyticus and V. harveyi [27].
  • Anti-idiotypic vaccines
A great deal of studies have shown that antibodies may have a regulatory effect on the immune system. Consequently, they have the conditions for making vaccines. The vaccine developed according to this principle is called an anti-idiotypic vaccine. As an anti-Id vaccine, anti-Id IgG is a vaccine that can provide protection by imitating the antigen epitope of V. harveyi. It may have a good application prospect in Asian fish culture against V. harveyi [28].
  • DNA vaccines
A series of experimental results suggest that DNA vaccines represented by pDV are positive vaccines against V. harveyi [29]. DNA vaccine can also be obtained by cloning the ompU gene into pEGFP-N1 plasmid. After the infection test of the turbot, the RPS was 51.4% [30]. Moreover, a V. harveyi DNA vaccine encoding TssJ antigen could produce a moderate protective role against V. harveyi in fish, and the relative percentage survival was 69.11% [25]. However, the exact route of protection in fish for these vaccines is still unclear at present [14].
  • mRNA vaccines
In 1990, the successful use of in vitro transcription (IVT) mRNA in animals was first reported, and related research has developed extremely rapidly since then. The production cost of the mRNA vaccine is low. The application safety is high, and the development turnaround time is short and pretty efficient. Therefore, the mRNA vaccine may have a better prospect compared with the traditional vaccine [31]. mRNA vaccines applied to aquatic animals are rare. We found a study on the mRNA vaccine against V. harveyi infection in fish. In this study, the researchers first used computational techniques to find potential T-and B-cell epitopes in V. harveyi hemolysin proteins and then sutured these epitopes into multi epitope mRNA vaccines. However, more experiments are needed to further prove the effectiveness of this vaccine [32].
Table 1. Control and prevention strategies of V. harveyi. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
Table 1. Control and prevention strategies of V. harveyi. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. harveyiAntibioticsCeftriaxone,
Doxycycline, Minocycline
Juvenile
hybrid groupers
NRBath,
Injection (IP)
[11]
Doxycycline, TetracyclineHippocampusNRInjection (IP)[12]
BacteriophagesPhage VhKM4FinfishNR [13]
VaccinesInactivatedMarine Red
Hybrid Tilapia
V. harveyi strain Vh1
(Formalin-Inactivated)
Injection (IP)[15]
E. coioidesVICVInjection (IP)[16]
Orange-spotted grouperV. Harveyi (formalin-killed,
Adjuvant: ISA763 AVG)
Injection (IP)[17]
TurbotV. Harveyi (formalin-killed,
Adjuvant: TMISA763 AVG)
Injection (IP)[18]
Pearl
gentian grouper
V. harveyi ZJ0603
(Formalin-killed, combine with β-glucanhas)
Injection (IP)[20]
AttenuatedGrouperNon-toxic V. harveyiBath,
Injection (IP)
[22]
Japanese flounderAttenuated mutant
V. Harveyi T4DM
Bath,
Injection (IP)
[24]
SubunitJapanese flounderRecombinant Vhp1Injection (IP)[21]
Golden pompanoAntigen encoding TssJInjection (IP)[25]
Orange-spotted
grouper
VirB11Injection (IP)[26]
Juvenile sea bassExpressed r-OmpK
of Vibrio
Injection (IP)[27]
Anti-idiotypicGrouperAnti-Id IgG (Fab)Injection (IP)[28]
DNAJapanese flounderPlasmid pDVInjection
(IP, IM)
[29]
TurbotPlasmid with OmpUInjection
(IP, IM)
[30]
mRNAFishand B-cell epitopes in hemolysin proteinNone[32]

2.2. V. vulnificus

V. vulnificus is a gram-negative bacterium that can cause wound infection and septicemia. Unlike other Vibrios, it is able to ferment lactose. According to genetic, biochemical and serological tests and host infection, V. vulnificus is currently classified into three biotypes. Biotype 1 strains are the source of most human infections, and biotype 2 strains mainly infect eels. The recently discovered biotype 3 has the biochemical characteristics of biotype 2 and 1 and can result in human wound infection [33].
In this era of environmental protection and sustainable development, the biological control strategy of Vibrio is gradually emerging, but there are few examples in fish farming.

Vaccines

  • Inactivated vaccines
Since V. vulnificus is one of the most harmful Vibrios to Asian fish culture, its vaccine control technology has been continuously developed (Table 2). The early vaccines against V. vulnificus are generally inactivated vaccines. For example, a formalin-inactivated V. vulnificus vaccine was effective at exciting a humoral antibody response in sex-reversed hybrid tilapia [34]. The combined vaccine (VICV) also can be effective against V. harveyi [16].
  • Subunit vaccines
There are also a few subunit vaccines against V. vulnificus under development. Some scientists have found that the expressed OmpU of V. vulnificus was capable of resisting the infection of V. vulnificus in Japanese eels and evidently raised the immune ability of eel. Therefore, the OmpU is proposed as a potential subunit vaccine against V. vulnificus [35].
  • Multivalent vaccines
Multivalent vaccines may be more practical in aquaculture due to their multiple protective effects. There is a bivalent protein that can be used against V. vulnificus and Edwardsiella anguillarum in Japanese eel as a vaccine. This fresh recombinant Omp vaccine with OmpA and OmpU shows its strong immunogenicity by significantly increasing the RPS rate of eels when infected with E. anguillarum and V. vulnificus [36].
In addition to these bivalent vaccines, a trivalent outer membrane protein, OmpII-U-A, containing part sequences of OmpU from V. vulnificus, OmpA from E. anguillarum, and OmpII from A. hydrophila, can also be made into a vaccine. According to the study of He et al. [37], the OmpII-U-A is able to prevent eel from being infected by V. vulnificus and A. hydrophila. This is the first time the expression and immunogenicity of a trivalent Omp are being reported, and the outcomes of this research will supply valuable guidelines for the exploration of multiplex vaccines in fish.
V. vulnificus has many bivalent and trivalent vaccines that can protect aquatic animals from A. hydrophila, E. anguillarum and other pathogens. These vaccines can provide ideas for the advancement of aquatic animal multiplex vaccines.

2.3. V. parahaemolyticus

V. parahaemolyticus is a Gram-negative, slightly halophilic bacterium that inhabits brackish aquatic environments such as coastal and estuarine waters. Apart from being pathogenic to aquatic organisms, V. parahaemolyticus is also known as a global food-borne pathogen and one of the most common causes of gastroenteritis in East Asia due to the local dietary habit of eating raw fish and shellfish [38,39].
V. parahaemolyticus is antibiotic-resistant, so it cannot be treated with antibiotics which is currently the most commonly used measure in Asian fish culture [40]. Consequently, there is a pressing need to exploit fresh, effective alternatives for antibiotics against V. parahaemolyticus (Table 3), while the vaccine is the most promising approach due to its economy, efficacy and safety in public awareness [40,41,42].

Vaccines

  • Inactivated vaccines
A polyvalent Vibrio vaccine had already been commercially used in Indonesian fish farming recently for tiger grouper (Mycteroperca tigris) and had shown effective protection against V. parahaemolyticus and two other Vibrio pathogens [43].
  • Recombinant vaccines
A study on cross-protection also found a recombinant cell vaccine had successfully induced an immune response to V. parahaemolyticus in juvenile sea bass by expressing the OmpK of Vibrio [27]. At the same time, another study has pointed out the limitation of recombinant OmpK in preparing diagnostic antibodies [44]. For this reason, using modern methods for understanding and developing new V. parahaemolyticus immunogenic proteins and antibodies are necessary [45,46].

2.4. V. cholerae

V. cholerae is a Gram-negative motile bacterium that can cause fatal pandemic diseases. There are millions of cholera cases worldwide every year, and the mortality rate is extremely high [47]. Consuming contaminated seafood by mistake is one of the reasons why people are infected with V. cholerae. As an important food-borne pathogen, V. cholerae is widely distributed in fish, which brings serious safety hazards to human and aquatic animal health [48].

2.4.1. Antibiotics

V. cholerae is one of the important pathogens related to fish vibriosis. In the bluegill sunfish that died in the farms of Guangdong around 2018, the pathogen identified was non-O1/non-O139 V. cholerae. The antibiotic sensitivity displayed that the isolated strain was sensitive to azithromycin, chloramphenicol, neomycin, norfloxacin, doxycycline, etc. The possible method to prevent infection of bluegill sunfish is to give neomycin or doxycycline for seven days [49].

2.4.2. Vaccines

After consulting a large number of data, we found that the current prevention and control of V. cholerae in Asian fish culture is still based on antibiotics, and no V. cholerae vaccine for aquatic animals has been found yet. Nevertheless, in recent decades, the misuse of antibiotics has resulted in the emergence and spread of drug-resistant bacteria in the environment, which is likely to pose a threat to public health [50]. Therefore, people are also constantly exploring new methods for the prevention and control of V. cholerae (Table 4).

2.4.3. Edible Antibodies

In 2015, a dominant non-O1 V. cholerae L1 strain was isolated from diseased carp in a breeding farm in Jiangsu, China. The researchers used egg yolk powder (IgY) against non-O1 vibrio cholerae to prove its effective effect on diseased carp [51]. This is one of the new methods to control V. cholerae.

2.4.4. Bacteriophages

In addition to the above emerging strategies, a phage prevention and control method has also been proposed [52], which has become a highly potential prevention and control measure in the future. Nevertheless, we have not found any information about the bacteriophage therapy of V. cholerae. This may be due to the difficulty in developing efficient phage administration mechanisms, different types of aquaculture systems, and the lack of a specific regulatory frame [53].
As a kind of pathogenic bacteria that is very harmful to Asian fish culture, the lack of V. cholerae vaccine prevention technology is indeed a big gap in the prevention of aquatic animal diseases.

2.5. V. anguillarum

V. anguillarum is a Gram-negative, comma-shaped rod bacterium that is polarly flagellated, non-sporeforming, halophilic and facultatively anaerobic. It is pathogenic to both marine and freshwater living animals, especially fish, showing classic symptoms of vibriosis, such as lethargy, abdominal distension, skin lesion and even internal and external ulceration [54,55].
In most circumstances, infection occurs by penetrating fish skin as V. anguillarum can enter through injuries or damaged mucous layers easily, and oral ingestion of V. anguillarum would also lead to vibriosis occasionally [56]. According to some studies, the outbreak of V. anguillarum is triggered by several factors, including physical, chemical and biological stresses [54].
The prevalence of V. anguillarum virulence has increased gradually as a result of the expansion of aquaculture [54]. Moreover, Asian fish culture losses caused by V. anguillarum-induced mortalities are extremely overwhelming over the world today. Therefore, even if the prevention and treatment of V. anguillarum still face major challenges, it is always a high priority for international aquatic research.
Control of V. anguillarum is usually carried out through the application of water quality management, vaccines, antibiotics and probiotics [43]. The other preventative and treatment procedures may not be as effective as vaccination in high-quality aquaculture but are still indispensable in maintaining fish production and economic status.

2.5.1. Antibiotics

The most common measure dealing with V. anguillarum infection in intensive Asian fish culture currently is still the use of chemicals and antibiotics [57], such as tetracycline, sulfaisozole and sulphamonomethioxine [55]. However, the intensive use of antibiotics leads to the bacterial resistance issue. That is precisely why scientists have made great efforts to find other effective and safe methods to control and prevent V. anguillarum infection. A successful example in Norwegian salmon farming shows that even with little use of antibiotics, fish production could still increase enormously [14].
In order to minimize the widespread utilization of antibiotics and to build a more sustainable Asian fish culture industry, scientists have investigated numerous alternatives to control V. anguillarum, including but not limited to antimicrobial peptides, probiotic bacterial strains, feed additives, immunostimulants and vaccines (Table 5).

2.5.2. Vaccines

  • Inactivated vaccines
Commercial aquaculture vaccines in the form of bacteria have mainly been used for the prevention of vibriosis for around 15 years in some countries and have played an important role in aquaculture [58]. These success cases encouraged and promoted the continuous study of inactivated vaccines to a great extent, and the inactivated vaccine is still the most common type of commercial vaccine against V. anguillarum until now. For example, Norvax-Vibrio Marine, AquaVac-Vibrio, ALPHA MARINE-Vibrio and MICRO ViB, which all composed of inactivated strains of both V. anguillarum serotypes O1 and O2 [54].
  • Attenuated live vaccines
The genetically engineered live V. anguillarum vaccine for turbot (strain MVAV6203) obtained a national first-class new veterinary drug certificate in China in 2019, which is able to control the breeding mortality of turbot within 10% when combined with a live attenuated vaccine against E. piscicida [59]. This vaccine could protect turbots, oliver flounders and zebrafish efficiently either by immersion or injection administration in previous research [60] and has been proven to be suitable for Tiger puffer as well [61]. In some subsequent studies, the biosafety of the live attenuated vaccine MVAV6203 was significantly improved without affecting its immune protection efficacy with a controllable bacterial lysis system being converted to a live attenuated vaccine strain MVAV6203 of V. anguillarum [62].
  • DNA and subunit vaccines
In addition to the use of whole-cell vaccines, we noticed that the development of DNA and subunit vaccines has been speeding up in recent years. Research and development of these two types of vaccines are mainly based on the immunological properties of V. anguilluram outer membrane proteins (OmpK, OmpU, OmpR, VAA) and flagellins (FlaA, FlaB) [63,64]. It was reported that a DNA vaccine based on the zinc metalloprotease EmpA already displayed gratifying results against V. anguillarum early in 2009 [65]. In recent years, several DNA and subunit vaccines based on V. anguillarum outer membrane proteins and their recombinant proteins have shown effective and long-lasting immunity [66,67,68,69]. It has also been proven in the study that particularly high protection against V. anguillarum infection exists when related proteins are formulated as bivalent vaccines [68].
Generally, injectable vaccines have the best protective effect on vibriosis, and intraperitoneal injection has been proven to be the most effective method of fish immunization [14]. In IP injection, oil adjuvants are usually used for protection. Nowadays, the preponderant vaccines on the market are polyvalent oil-adjuvanted vaccines. On the one hand, oil adjuvants have been related to side effects such as pigmentation, inflammation, growth disorders, visceral fiber adhesion and granulomatous lesion formation [70]. On the other hand, inactivated vaccines cannot provide ample protection unless adding adjuvants to enhance the effectiveness of the vaccine [14]. Thus, researchers have been looking for alternative adjuvants with fewer side effects and effective as well.
Adjuvants administrated with inactivated V. anguillarum vaccines are supposed to induce effective protection, similarly to other adjuvants, but cause fewer side effects [71,72]. It is the same case in autogenous vaccines, which confer high levels of immune protection and persistent immunity, but with high side effects. Thus, in order to increase protection and reduce or eliminate the side effects at the same time, liquid paraffin adjuvants have been suggested to be put into use [73]. Moreover, when it comes to DNA and subunit vaccines, adjuvants are mostly used to enhance the immune response of the vaccines [74,75].
The most non-negligible defect of injectable vaccines is that they are not suitable for either small or juvenile fish, which could easily cause secondary infections by injection. For this reason, even though not as effective as injectable vaccines, oral and immersion vaccines are still used in some areas of aquaculture. These two types of vaccines are based on V. anguillarum outer membrane proteins [76], V. anguillarum serotypes O1 and O2 [77], avirulent environmental isolates [78] or an attenuated V. anguillarum strain [79]. A conclusion can be made that the best answer for V. angullarum vaccine would be: easily manipulated, suitable for both adult and juvenile fish, and demonstrate effectiveness against a broad spectrum of Vibrio pathogens.
To create the ideal novel vaccine, undoubtedly, the most significant part will be the identification of common antigens [45]. The use of modern reverse vaccinology could make it come true by predicting potential protective antigens and epitopes, which could aid in narrowing down peptide selection in designing suitable vaccines [80].
Table 5. Control and prevention strategies of V. anguillarum. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
Table 5. Control and prevention strategies of V. anguillarum. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. anguillarumVaccinesInactivatedFishInactivated strains of V. anguillarum serotypes O2 and O1Injection (IP)[54]
Attenuated Turbot, Oliver flounder,
Zebrafish, Tiger puffer
Genetically engineered live
V. anguillarum
Injection[59,60,61]
Zebrafishlive attenuated
V. anguillarum strain MVAV6203
Injection (IP)[62]
SubunitParalichthys olivaceusRecombinant protein (rOmpK)Injection[69]
DNAJapanese flounderZinc metalloprotease EmpAInjection (IM)[65]
Paralichthys olivaceusBicistronic plasmids (p-OmpK-CCL19 and p-OmpK-CCL4)Injection (IM)[66]
FlounderDNA plasmid
encoding the VAA of V. anguillarum
Injection (IP)[67]
Paralichthys olivaceusPlasmid OmpK
from V. anguillarum plus cyclosporine A
Injection[69]

2.6. V. mimicus

V. mimicus is a Gram-negative bacterium that is a species closely related to V. cholerae, and it is found to be distributed in freshwater, brackish water and seawater [81]. V. mimicus infection has a short disease course and high mortality, which has brought serious economic losses to Asian fish culture.

2.6.1. Antibiotics

In 2011, Vibrio mimicus infection occurred in cultured Pelteobagrus fulvidraco in Guangdong and Guangxi in southern China [82]. Shortly afterward, a study published in 2014 showed that V. mimicus can also naturally infect southern catfish and Zhengchuan catfish and cause a large number of deaths. In the drug sensitivity test, all of the V. mimicus isolates from catfish were sensitive to gentamicin, florfenicol, lomefloxacin, and ciprofloxacin [83]. This provides ideas for the antibiotic control of V. mimicus.

2.6.2. Vaccines

  • DNA vaccines
In order to better prevent V. mimicus infection, the development of related excellent vaccines is also essential (Table 6). Since V. mimicus typically infects intestinal tracts, the idea of developing an oral DNA vaccine that can induce intestinal mucosal immunity is quite wise. Whereas, due to digestive tract degradation, oral naked DNA vaccine often has poor immunogenicity. Thereby, researchers considered using targeted DNA delivery strategies to improve the efficacy of vaccines. In recent years, based on the identification of the epitopes of OmpU and VMH 18 proteins from V. mimicus, a novel V. mimicus dual-targeted DNA vaccine constructed using BGS and ICLP as exogenous and endogenous targeted delivery vectors, respectively, was developed. Through the evaluation of the efficacy of oral administration to grass carp, it can be reliably concluded that this double-targeted DNA vaccine can cause remarkably higher systemic and intestinal mucosal immune protection than both single-targeted and naked DNA vaccines [84,85,86]. In its follow-up experiments, researchers have conducted some research on the impact of the vaccine on the response of grass carp intestinal microflora to the vaccine and the potential regulatory molecular mechanism of enhancing intestinal mucosal immunity [87,88].
  • Attenuated live vaccines
In addition to DNA vaccines, the development of live attenuated vaccines against V. mimicus has also made some progress. Identifications of several possible virulence genes have been made in order to determine the complete genome sequence of V. mimicus strain sccf01 related to yellow catfish infection, which contributed to the development of subunit and lives attenuated vaccines by providing a genetic basis. Moreover, the immersion challenge test depicted that strain SCCF01 can adhere and colonize the mucosal surface, which is hopeful for the development of an attenuated vaccine [89].
The safety of attenuated vaccines can be effectively improved by introducing more than one attenuating phenotype. A successful example using the natural transformation of strain sccf01 to knock out genes provides a brand new way to construct targeted mutants in V. mimicus and also helps to eliminate the risk of virulence reversal caused by recombination events. By this means, the research on the pathogenic mechanism of V. mimicus and the development of attenuated vaccines have all been greatly improved [90].

2.7. V. alginolyticus

V. alginolyticus is a gram-negative bacterium that is usually distributed in coastal and estuarine environments and causes vibriosis in humans and fish. It has generated immense economic losses to the Asian fish culture industry and caused a menace to public hygiene [91].

2.7.1. Antibiotics

Antibiotics are the most commonly used method to control V. alginolyticus. The drug sensitivity test of V. alginolyticus infected tilapia showed that treatment with florfenicol, enrofloxacin or terramycin could reduce the mortality of infected Nile tilapia [92]. What is more, the results of another drug sensitivity test on V. alginolyticus identified in the hippocampus cultured in eastern China showed that it was highly sensitive to doxycycline and tetracycline as well [12].
Even though V. alginolyticus remains sensitive to some antibiotics, with the widespread use of antibiotics, many studies have proved that V. alginolyticus has developed resistance to many antibiotics [93,94]; as a result, there is an urgent need to find some non-chemical control methods that can replace antibiotics.

2.7.2. Probiotics

Probiotics have also been considered effective methods for V. alginolyticus controlling. For example, Pseudoalteromonas sp. IBRL PD4.8 is a promising natural antifouling agent that inhibits the growth of five contaminating bacteria and V. alginolyticus FB3 biofilms [95].

2.7.3. Bacteriophages

A study revealed that with its extremely strong lytic effect, phage VP01 shows a strong underlying influence on the growth of V. alginolyticus and on biofilm formation [96]. Furthermore, it has been reported that a few bacteriophages may be powerful candidates for the treatment of V. alginolyticus infection, including bacteriophage VEN [97], HH109 [98], as well as phage valsw3-3 with stronger infectivity, better pH value and thermal stability [99]. Therefore, phage therapy tends to be a promising alternative approach to antibiotics in the future.

2.7.4. Antimicrobials from Natural Sources

In addition, some antimicrobials from natural sources have also been used to prevent V. alginolyticus infection. The sources of this method are very rich. For example, compared with the parent phages, Phage Endolysins Lysqdvp001 has better lytic and antibacterial activity, which might act as possible antimicrobials against multidrug oppose V. parahaemolyticus and V. alginolyticus [100]. Moreover, Exogenous malic acid and taurine can improve the survival ratio of zebrafish infected with V. alginolyticus [101]. Additionally, supplementary feeding of astaxanthin has been proven to be resultful in consolidating fish immunocompetence, and illness resistance oppose V. alginolyticus infection [102]. Moreover, extracts from the secondary metabolites of some heterotrophic bacteria can also inhibit the growth of V. alginolyticus [103].

2.7.5. Vaccines

  • Attenuated live vaccines
There are many studies on live attenuated vaccines of V. alginolyticus (Table 7). The high vaccination potency makes the hfq mutant a prospective attenuated live vaccine to defend fish from pathogenic V. alginolyticus infection [104]. Moreover, ∆acfA can induce a resultful and long-lasting immune response in pearl gentian grouper and can also be a resultful attenuated live vaccine candidate for the prevention of V. alginolyticus infections [105]. In addition, a resultful live vaccine is the HY9901 ∆hop mutant, which can be used against V. alginolyticus in grouper [106]. Similarly, another resultful live attenuated vaccine against V. alginolyticus infection in pearl gentian fish is HY9901ΔvscB mutant [107]. Results of a study indicated ∆clpP showing great potential to be a live attenuated vaccine as well [108]. The previously mentioned attenuated candidate vaccine of V. harveyi has a cross-protective effect on V. alginolyticus [24], while the live attenuated vaccine of V. alginolyticus T3SS has also been proven to be protective [109]. A recent study has developed an unreported method of preparing live attenuated V. alginolyticus vaccination by incubating the bacteria in a high concentration of magnesium to attenuate the virulence of the bacteria [110].
  • Recombinant vaccines
Recombinant vaccines have also been studied in V. alginolyticus prevention. Fish vaccinated with recombinant OmpU vaccine were proved to be highly resistant to attack by V. alginolyticus, and the OmpK and OmpW vaccines are similar to their principle [111,112]. Moreover, the FlaC protein demonstrated a significant immune protection function against V. alginolyticus infection [113], and they are expected to become potential vaccines against V. alginolyticus.
Since aquatic product diseases are often caused by multiple pathogens, it is particularly important to develop vaccines against more than one pathogen [114]. The two vaccines mentioned above in other Vibrio vaccines also have the same immune effects on Vibrio alginolyticus [16,27].
  • DNA vaccines
A DNA vaccine is also a promising technology used against V. alginolyticus. It has been proved that the plasmid DNA coding flagellin flaA gene can effectively immunize red snappers. [115]. In another study, the ompW gene was inserted into the pcDNA plasmid to obtain a DNA vaccine. After the animal infection test, the RPS of this vaccine was 92.53% [116]. Additionally, among the 16 DNA vaccines constructed in an experiment, 3 (AT730_22220, AT730_22910 and AT730_21605) of them tended to be potential candidates for multivalent vaccines as being protective as opposed to V. alginolyticus infection with 47–66.7% added survival contrasted to the control [117].
  • BGs vaccines
Recently, a newly constructed V. alginolyticus ghost, VaBGs, has been proven to be a secure and resultful vaccine for preventing V. alginolyticus infection. Moreover, this kind of BGs vaccine has also been developed in other pathogens as a new technology [118].
The research on the control technology of V. alginolyticus is also relatively mature, and the types of vaccines against V. alginolyticus are diverse. Turning these vaccines into more commercial vaccines for application is the next goal of V. alginolyticus Prevention.
Table 7. Control and prevention strategies of V. alginolyticus. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
Table 7. Control and prevention strategies of V. alginolyticus. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. alginolyticusAntibioticsFlorfenicol, Enrofloxacin, TerramycinNile tilapia NRInjection (IP)[92]
Doxycycline, TetracyclineHippocampus NRInjection (IP)[12]
ProbioticsPseudoalteromonas sp. IBRL PD4.8None NRNone[95]
Antimicrobials from natural sourcesPhage Endolysins Lysqdvp001None NRNone[100]
Exogenous malic acid, TaurineZebrafish NRInjection (IP)[101]
AstaxanthinFish NROral[102]
Secondary metabolite
(From Bacillus sp. strain JS04)
None NRNone[103]
BacteriophagesPhage VP01, Phage VEN
Phage HH109, Phage valsw3-3
None NRNone[96,97,98,99]
VaccinesInactivatedE. coioidesVICVInjection (IP)[16]
AttenuatedZebrafishhfq mutantInjection (IM)[104]
Pearl gentian grouperacfA, HY9901∆hop,
HY9901ΔvscB,
clpP mutant
Injection (IP)[105,106,107,108]
Japanese flounderAttenuated mutant
V. harveyi T4DM
Injection (IP),
Bath
[24]
ZebrafishAttenuated
V. alginolyticus T3SS
Injection (IM)[109]
ZebrafishAttenuated
V. alginolyticus (Mg)
Injection (IM)[110]
RecombinantJuvenile sea bassExpressed r-OmpK
of Vibrio
Injection (IP)[27]
DNARed snapperPlasmid encoding flaAInjection[115]
Crimson snapperpcDNA plasmid with OmpWInjection (IM)[116]
BGsLarge yellow croakerV. alginolyticus
bacterial ghosts
Injection (IP)[118]

3. Discussion

Aquaculture production in Asia has increased significantly in recent decades, while worryingly, the development speed of aquatic disease prevention and control technology has been far behind the development of this fast-paced industry.
Vibriosis will remain to be one of the major challenges for the development of Asian aquaculture, with increasing breeding density and shorter breeding cycles. As one of the emerging methods to prevent and control vibriosis in aquaculture, the vaccine has a good application prospect. It is foreseeable that the future development trend of the Vibrio vaccine will be more convenient, cost-effective and environmentally friendly [14].
However, the application of Vibrio vaccines in Asian aquaculture still faces the following problems currently. First and foremost, through our investigation, we found that most of the current Vibrio vaccines are injected and rarely bathed. In aquaculture, fish often have a complex growth environment and a large number, so the implementation of injectable vaccines in the actual production is difficult. Moreover, the protective effect of oral vaccines is limited [119]. Secondly, the safety of fish vaccines has always been a concern [120]. It is truly that most of the Vibrio vaccines we investigated are still in the lab testing phase, which is either immature or subject to regulatory restrictions due to their uncertain security. Last but not least, the aquaculture industry chain and regulatory system in many Asian countries have yet to be perfect. These are important because only positive interaction between industry participants gives incentives to innovate and development of new technologies which could solve the facing problems of aquaculture industry.
The development of Vibrio vaccines in Asian aquaculture is still in the innovative research phase, and most innovations are progressive. However, there is no doubt that once the vaccine technology is mature, it will be widely used as the most cost-effective method of combating Vibrio diseases. Meanwhile, the aquaculture industry is exploring other solutions for Vibrio diseases as well, such as bacteriophages, nanoparticles and breeding for disease resistance.

4. Conclusions

In this review, we introduce and discuss the control and prevention strategies of seven species of Vibrio in Asian fish culture. Great progress has been made in this field in the past two decades. Although antibiotic treatment is widely used, with the gradual increase of Vibrio resistance to antibiotics, it is urgent to find some alternative non-chemical prevention and treatment methods. Probiotics, bacteriophages, natural extracts and other methods are created to meet the requirements of environmental protection and sustainable development in Asian fish culture and have great development potential in the future. There are more and more types of vaccines against Vibrio: attenuated, inactivated, recombinant and DNA vaccines. Even now, the Vibrio mRNA vaccine applied in aquaculture is being studied. The effectiveness of most of these vaccines has been verified in the laboratory.
When we investigated the Vibrio vaccine technology, we found that most of the vaccine trials were still limited to laboratory investigation, and its use in the actual aquaculture environment still needs further testing. Vibrio vaccine serves the aquaculture industry, so designers should also fully consider the development cost of the vaccine and the vaccination cost in practical application when developing it, which is quite an important factor in future vaccine promotion.
The seven Vibrios were selected in this paper because they have a related vaccine or the vaccine created is in urgent need. When investigating the prevention and control strategies of Vibrio, we found that at least 30 kinds of Vibrios can cause harm to the Asian fish culture industry, but less than 10 kinds of Vibrios have vaccine prevention and control technology. The V. cholerae selected in this paper is one of the Vibrios that has not yet found vaccine control technology. It can be seen that there is still a big gap in the prevention and control strategy of the Vibrio vaccine in Asian fish culture.
In general, this paper summarizes several existing measures and the latest technology of Vibrio control, which will provide ideas for better prevention and control of vibriosis in future Asian fish cultures.

Author Contributions

Writing—original draft preparation, K.X., Y.W., W.Y. and H.C.; writing—review and editing, L.H. and Y.Z.; project administration, L.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China under contract No. 32173016, the Project of Subsidy Funds for Marine Economic Development in Fujian under grant FJHJF-L-2022-20, the major program of Science and Technology Planning of Xiamen under Contract No. 3502Z20211004, the Fujian Engineering Research Center of Aquatic Breeding and Healthy Aquaculture, under Contract No. DF201903, and the Natural Science Foundation of Fujian (No. 2019J01695 and 2021J01823).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Naylor, R.L.; Hardy, R.W.; Buschmann, A.H.; Bush, S.R.; Cao, L.; Klinger, D.H.; Little, D.C.; Lubchenco, J.; Shumway, S.E.; Troell, M. A 20-year retrospective review of global aquaculture. Nature 2021, 591, 551–563. [Google Scholar] [CrossRef] [PubMed]
  2. Boyd, C.E.; McNevin, A.A.; Davis, R.P. The contribution of fisheries and aquaculture to the global protein supply. Food Secur. 2022, 14, 805–827. [Google Scholar] [CrossRef] [PubMed]
  3. Stentiford, G.D.; Holt, C.C. Global adoption of aquaculture to supply seafood. Environ. Res. Lett. 2022, 17, 041003. [Google Scholar] [CrossRef]
  4. Thompson, F.L.; Iida, T.; Swings, J. Biodiversity of Vibrios. Microbiol. Mol. Biol. Rev. 2004, 68, 403–431. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Schar, D.; Klein, E.Y.; Laxminarayan, R.; Gilbert, M.; Van Boeckel, T.P. Global trends in antimicrobial use in aquaculture. Sci. Rep. 2020, 10, 1–9. [Google Scholar] [CrossRef] [PubMed]
  6. Verschuere, L.; Rombaut, G.; Sorgeloos, P.; Verstraete, W. Probiotic Bacteria as Biological Control Agents in Aquaculture. Microbiol. Mol. Biol. Rev. 2000, 64, 655–671. [Google Scholar] [CrossRef] [Green Version]
  7. Zhou, Q.; Zhu, X.; Li, Y.; Yang, P.; Wang, S.; Ning, K.; Chen, S. Intestinal microbiome-mediated resistance against vibriosis for Cynoglossus semilaevis. Microbiome 2022, 10, 153. [Google Scholar] [CrossRef]
  8. Zhao, N.; Zhang, B.; Xu, Z.; Jia, L.; Li, M.; He, X.; Bao, B. Detecting Cynoglossus semilaevis infected with Vibrio harveyi using micro RNAs from mucous exosomes. Mol. Immunol. 2020, 128, 268–276. [Google Scholar] [CrossRef]
  9. Miccoli, A.; Manni, M.; Picchietti, S.; Scapigliati, G. State-of-the-Art Vaccine Research for Aquaculture Use: The Case of Three Economically Relevant Fish Species. Vaccines 2021, 9, 140. [Google Scholar] [CrossRef]
  10. Zhang, X.-H.; He, X.; Austin, B. Vibrio harveyi: A serious pathogen of fish and invertebrates in mariculture. Mar. Life Sci. Technol. 2020, 2, 231–245. [Google Scholar] [CrossRef]
  11. Shen, G.M.; Shi, C.Y.; Fan, C.; Jia, D.; Wang, S.Q.; Xie, G.S.; Li, G.Y.; Mo, Z.L.; Huang, J. Isolation, identification and pathogenicity of Vibrio harveyi, the causal agent of skin ulcer disease in juvenile hybrid groupers Epinephelus fuscoguttatus × Epinephelus lanceolatus. J. Fish Dis. 2017, 40, 1351–1362. [Google Scholar] [CrossRef] [PubMed]
  12. Xie, J.; Bu, L.; Jin, S.; Wang, X.; Zhao, Q.; Zhou, S.; Xu, Y. Outbreak of vibriosis caused by Vibrio harveyi and Vibrio alginolyticus in farmed seahorse Hippocampus kuda in China. Aquaculture 2020, 523, 735168. [Google Scholar] [CrossRef]
  13. Lal, T.M.; Sano, M.; Ransangan, J. Isolation and Characterization of Large Marine Bacteriophage (Myoviridae), VhKM4 Infecting Vibrio harveyi. J. Aquat. Anim. Health 2017, 29, 26–30. [Google Scholar] [CrossRef] [PubMed]
  14. Mondal, H.; Thomas, J. A review on the recent advances and application of vaccines against fish pathogens in aquaculture. Aquac. Int. 2022, 30, 1971–2000. [Google Scholar] [CrossRef]
  15. Abu Nor, N.; Zamri-Saad, M.; Md Yasin, I.S.; Salleh, A.; Mustaffa-Kamal, F.; Matori, M.F.; Azmai, M.N.A. Efficacy of Whole Cell Inactivated Vibrio harveyi Vaccine against Vibriosis in a Marine Red Hybrid Tilapia (Oreochromis niloticus × O. mossambicus) Model. Vaccines 2020, 8, 734. [Google Scholar] [CrossRef] [PubMed]
  16. Huang, Z.; Tang, J.; Li, M.; Fu, Y.; Dong, C.; Zhong, J.F.; He, J. Immunological evaluation of Vibrio alginolyticus, Vibrio harveyi, Vibrio vulnificus and infectious spleen and kidney necrosis virus (ISKNV) combined-vaccine efficacy in Epinephelus coioides. Vet. Immunol. Immunopathol. 2012, 150, 61–68. [Google Scholar] [CrossRef]
  17. Nguyen, H.T.; Nguyen, T.T.T.; Tsai, M.-A.; Ya-Zhen, E.; Wang, P.-C.; Chen, S.-C. A formalin-inactivated vaccine provides good protection against Vibrio harveyi infection in orange-spotted grouper (Epinephelus coioides). Fish Shellfish Immunol. 2017, 65, 118–126. [Google Scholar] [CrossRef]
  18. Xu, W.; Jiao, C.; Bao, P.; Liu, Q.; Wang, P.; Zhang, R.; Liu, X.; Zhang, Y. Efficacy of Montanide™ ISA 763 A VG as aquatic adjuvant administrated with an inactivated Vibrio harveyi vaccine in turbot (Scophthalmus maximus L.). Fish Shellfish Immunol. 2018, 84, 56–61. [Google Scholar] [CrossRef]
  19. Harikrishnan, R.; Kim, J.-S.; Balasundaram, C.; Heo, M.-S. Vaccination effect of liposomes entrapped whole cell bacterial vaccine on immune response and disease protection in Epinephelus bruneus against Vibrio harveyi. Aquaculture 2012, 342–343, 69–74. [Google Scholar] [CrossRef]
  20. Wei, G.; Tan, H.; Ma, S.; Sun, G.; Zhang, Y.; Wu, Y.; Cai, S.; Huang, Y.; Jian, J. Protective effects of beta-glucan as adjuvant combined inactivated Vibrio harveyi vaccine in pearl gentian grouper. Fish Shellfish Immunol. 2020, 106, 1025–1030. [Google Scholar] [CrossRef]
  21. Cheng, S.; Zhang, W.-W.; Zhang, M.; Sun, L. Evaluation of the vaccine potential of a cytotoxic protease and a protective immunogen from a pathogenic Vibrio harveyi strain. Vaccine 2010, 28, 1041–1047. [Google Scholar] [CrossRef] [PubMed]
  22. Bai, J.-Y.; Long, H.; Cui, J.; Zhang, X.; Cai, X.-N.; Xie, Z.-Y. Characterization of a pathogenic Vibrio harveyi strain from diseased Epinephelus coioides and evaluation of different methods to control its infection. Aquaculture 2020, 526, 735371. [Google Scholar] [CrossRef]
  23. Hu, Y.-H.; Cheng, S.; Zhang, M.; Sun, L. Construction and evaluation of a live vaccine against Edwardsiella tarda and Vibrio harveyi: Laboratory vs. mock field trial. Vaccine 2011, 29, 4081–4085. [Google Scholar] [CrossRef] [PubMed]
  24. Hu, Y.-H.; Deng, T.; Sun, B.-G.; Sun, L. Development and efficacy of an attenuated Vibrio harveyi vaccine candidate with cross protectivity against Vibrio alginolyticus. Fish Shellfish Immunol. 2012, 32, 1155–1161. [Google Scholar] [CrossRef]
  25. Sun, Y.; Ding, S.; He, M.; Liu, A.; Long, H.; Guo, W.; Cao, Z.; Xie, Z.; Zhou, Y. Construction and analysis of the immune effect of Vibrio harveyi subunit vaccine and DNA vaccine encoding TssJ antigen. Fish Shellfish Immunol. 2019, 98, 45–51. [Google Scholar] [CrossRef]
  26. Atujona, D.; Huang, Y.; Wang, Z.; Jian, J.; Cai, S. Vibrio harveyi (VirB11) recombinant vaccine development against vibriosis in orange-spotted grouper (Epinephelus coioides). Aquac. Res. 2019, 50, 2628–2634. [Google Scholar] [CrossRef]
  27. Silvaraj, S.; Md Yasin, I.S.; MMAK; Saad, M.Z. Elucidating the Efficacy of Vaccination against Vibriosis in Lates calcarifer Using Two Recombinant Protein Vaccines Containing the Outer Membrane Protein K (r-OmpK) of Vibrio alginolyticus and the DNA Chaperone J (r-DnaJ) of Vibrio harveyi. Vaccines 2020, 8, 660. [Google Scholar] [CrossRef]
  28. Huang, W.-L.; Chuang, S.-C.; Yang, C.-D. Anti-Idiotype Vaccine Provides Protective Immunity Against Vibrio Harveyi in Grouper (Epinephelus coioides). Vaccines 2019, 7, 210. [Google Scholar] [CrossRef] [Green Version]
  29. Hu, Y.-H.; Sun, L. A bivalent Vibrio harveyi DNA vaccine induces strong protection in Japanese flounder (Paralichthys olivaceus). Vaccine 2011, 29, 4328–4333. [Google Scholar] [CrossRef]
  30. Wang, Q.; Chen, J.; Liu, R.; Jia, J. Identification and evaluation of an outer membrane protein OmpU from a pathogenic Vibrio harveyi isolate as vaccine candidate in turbot (Scophthalmus maximus). Lett. Appl. Microbiol. 2011, 53, 22–29. [Google Scholar] [CrossRef]
  31. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Islam, S.I.; Mou, M.J.; Sanjida, S.; Tariq, M.; Nasir, S.; Mahfuj, S. Designing a novel mRNA vaccine against Vibrio harveyi infection in fish: An immunoinformatics approach. Genom. Inform. 2022, 20, e11. [Google Scholar] [CrossRef] [PubMed]
  33. Bisharat, N.; Agmon, V.; Finkelstein, R.; Raz, R.; Ben-Dror, G.; Lerner, L.; Soboh, S.; Colodner, R.; Cameron, D.N.; Wykstra, D.L.; et al. Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Lancet 1999, 354, 1421–1424. [Google Scholar] [CrossRef] [PubMed]
  34. Shoemaker, C.A.; Lafrentz, B.R.; Klesius, P.H. Vaccination of sex reversed hybrid tilapia (Oreochromis niloticus × O. aureus) with an inactivated Vibrio vulnificus vaccine. Biologicals 2011, 39, 424–429. [Google Scholar] [CrossRef] [PubMed]
  35. Le, H.; Lihua, D.; Jianjun, F.; Peng, L.; Songlin, G. Immunogenicity study of an expressed outer membrane protein U of Vibrio vulnificus in Japanese eel (Anguilla japonica). J. Appl. Microbiol. 2018. Online ahead of print. [Google Scholar] [CrossRef]
  36. Guo, S.; Hu, L.; Feng, J.; Lin, P.; He, L.; Yan, Q. Immunogenicity of a bivalent protein as a vaccine against Edwardsiella anguillarum and Vibrio vulnificus in Japanese eel (Anguilla japonica). Microbiologyopen 2018, 8, e00766. [Google Scholar] [CrossRef] [Green Version]
  37. He, L.; Wu, L.; Lin, P.; Zhai, S.; Guo, S.; Xiao, Y.; Wan, Q. First expression and immunogenicity study of a novel trivalent outer membrane protein (OmpII-U-A) from Aeromonas hydrophila, Vibrio vulnificus and Edwardsiella anguillarum. Aquaculture 2020, 519, 734932. [Google Scholar] [CrossRef]
  38. Jun, J.W.; Kim, J.H.; Choresca, C.H., Jr.; Shin, S.P.; Han, J.E.; Han, S.Y.; Chai, J.Y.; Park, S.C. Isolation, molecular characterization, and antibiotic susceptibility of Vibrio parahaemolyticus in Korean seafood. Foodborne Pathog. Dis. 2012, 9, 224–231. [Google Scholar] [CrossRef]
  39. Lee, J.-K.; Jung, D.-W.; Eom, S.-Y.; Oh, S.-W.; Kim, Y.; Kwak, H.-S.; Kim, Y.-H. Occurrence of Vibrio parahaemolyticus in oysters from Korean retail outlets. Food Control. 2008, 19, 990–994. [Google Scholar] [CrossRef]
  40. Hu, Q.; Chen, L. Virulence and Antibiotic and Heavy Metal Resistance of Vibrio parahaemolyticus Isolated from Crustaceans and Shellfish in Shanghai, China. J. Food Prot. 2016, 79, 1371–1377. [Google Scholar] [CrossRef]
  41. Kang, C.-H.; Shin, Y.; Jang, S.; Yu, H.; Kim, S.; An, S.; Park, K.; So, J.-S. Characterization of Vibrio parahaemolyticus isolated from oysters in Korea: Resistance to various antibiotics and prevalence of virulence genes. Mar. Pollut. Bull. 2017, 118, 261–266. [Google Scholar] [CrossRef] [PubMed]
  42. Friedman, M. Antibiotic-Resistant Bacteria: Prevalence in Food and Inactivation by Food-Compatible Compounds and Plant Extracts. J. Agric. Food Chem. 2015, 63, 3805–3822. [Google Scholar] [CrossRef] [PubMed]
  43. Istiqomah, I.; Sukardi; Murwantoko; Isnansetyo, A. Review Vibriosis Management in Indonesian Marine Fish Farming. E3S Web Conf. 2020, 147, 01001. [Google Scholar] [CrossRef] [Green Version]
  44. Wang, W.; Guo, S.; Gao, Y.; Liang, X.; Liu, L.; Pan, S. Comparative immunogenicity of outer membrane protein K and whole-cell antigens of Vibrio parahaemolyticus for diagnosis. Lett. Appl. Microbiol. 2021, 73, 460–470. [Google Scholar] [CrossRef] [PubMed]
  45. Chukwu-Osazuwa, J.; Cao, T.; Vasquez, I.; Gnanagobal, H.; Hossain, A.; Machimbirike, V.I.; Santander, J. Comparative Reverse Vaccinology of Piscirickettsia salmonis, Aeromonas salmonicida, Yersinia ruckeri, Vibrio anguillarum and Moritella viscosa, Frequent Pathogens of Atlantic Salmon and Lumpfish Aquaculture. Vaccines 2022, 10, 473. [Google Scholar] [CrossRef]
  46. Liu, X.; Yang, M.-J.; Wang, S.-N.; Xu, D.; Li, H.; Peng, X.-X. Differential Antibody Responses to Outer Membrane Proteins Contribute to Differential Immune Protections between Live and Inactivated Vibrio parahemolyticus. J. Proteome Res. 2018, 17, 2987–2994. [Google Scholar] [CrossRef]
  47. Peterson, K.M.; Gellings, P.S. Multiple intraintestinal signals coordinate the regulation of Vibrio cholerae virulence determinants. Pathog. Dis. 2018, 76, ftx126. [Google Scholar] [CrossRef] [Green Version]
  48. Ahmed, H.A.; El Bayomi, R.M.; Hussein, M.A.; Khedr, M.H.; Remela, E.M.A.; El-Ashram, A.M. Molecular characterization, antibiotic resistance pattern and biofilm formation of Vibrio parahaemolyticus and V. cholerae isolated from crustaceans and humans. Int. J. Food Microbiol. 2018, 274, 31–37. [Google Scholar] [CrossRef]
  49. Yang, Y.; Zhang, H.; Liu, Y.; Dong, J.; Xu, N.; Yang, Q.; Zhou, S.; Ai, X. Identification of Vibrio cholerae as a bacterial pathogen of bluegill sunfish. Aquac. Rep. 2022, 23, 101092. [Google Scholar] [CrossRef]
  50. Elmahdi, S.; DaSilva, L.V.; Parveen, S. Antibiotic resistance of Vibrio parahaemolyticus and Vibrio vulnificus in various countries: A review. Food Microbiol. 2016, 57, 128–134. [Google Scholar] [CrossRef]
  51. Gao, X.; Chen, N.; Zhang, Y.; Zhang, X.; Bing, X. Non-O1 Vibrio cholerae pathogen from Cyprinus carpio and control with anti-non-O1 V. cholerae egg yolk powder (IgY). Aquaculture 2017, 479, 69–74. [Google Scholar] [CrossRef]
  52. Wittebole, X.; De Roock, S.; Opal, S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2013, 5, 226–235. [Google Scholar] [CrossRef] [PubMed]
  53. Plaza, N.; Castillo, D.; Pérez-Reytor, D.; Higuera, G.; García, K.; Bastías, R. Bacteriophages in the control of pathogenic vibrios. Electron. J. Biotechnol. 2018, 31, 24–33. [Google Scholar] [CrossRef]
  54. Frans, I.; Michiels, C.; Bossier, P.; Willems, K.A.; Lievens, B.; Rediers, H. Vibrio anguillarum as a fish pathogen: Virulence factors, diagnosis and prevention. J. Fish Dis. 2011, 34, 643–661. [Google Scholar] [CrossRef] [PubMed]
  55. Hickey, M.E.; Lee, J.L. A comprehensive review of Vibrio (Listonella) anguillarum: Ecology, pathology and prevention. Rev. Aquac. 2017, 10, 585–610. [Google Scholar] [CrossRef]
  56. Weber, B.; Chen, C.; Milton, D.L. Colonization of fish skin is vital for Vibrio anguillarum to cause disease. Environ. Microbiol. Rep. 2010, 2, 133–139. [Google Scholar] [CrossRef] [PubMed]
  57. Soliman, W.S.; Shaapan, R.M.; Mohamed, L.A.; Gayed, S.S. Recent biocontrol measures for fish bacterial diseases, in particular to probiotics, bio-encapsulated vaccines, and phage therapy. Open Vet. J. 2019, 9, 190–195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Sun, Y.; Liu, C.-S.; Sun, L. A multivalent killed whole-cell vaccine induces effective protection against Edwardsiella tarda and Vibrio anguillarum. Fish Shellfish Immunol. 2011, 31, 595–599. [Google Scholar] [CrossRef]
  59. Bao, P.; Sun, X.; Liu, Q.; Zhang, Y.; Liu, X. Synergistic effect of a combined live Vibrio anguillarum and Edwardsiella piscicida vaccine in turbot. Fish Shellfish Immunol. 2019, 88, 84–90. [Google Scholar] [CrossRef]
  60. Liu, X.; Jiao, C.; Ma, Y.; Wang, Q.; Zhang, Y. A live attenuated Vibrio anguillarum vaccine induces efficient immunoprotection in Tiger puffer (Takifugu rubripes). Vaccine 2018, 36, 1460–1466. [Google Scholar] [CrossRef]
  61. Wang, S.; Liu, Q.; Cai, M.; Wang, Q.; Zhang, Y. Fermentation preparation of recombinant Vibrio anguillarum vaccine with heterogeneous antigen display. Prep. Biochem. Biotechnol. 2013, 43, 79–94. [Google Scholar] [CrossRef]
  62. Chu, T.; Guan, L.; Shang, P.; Wang, Q.; Xiao, J.; Liu, Q.; Zhang, Y. A controllable bacterial lysis system to enhance biological safety of live attenuated Vibrio anguillarum vaccine. Fish Shellfish Immunol. 2015, 45, 742–749. [Google Scholar] [CrossRef]
  63. Kwon, H.C.; Kang, Y.J. Effects of a subunit vaccine (FlaA) and immunostimulant (CpG-ODN 1668) against Vibrio anguillarum in tilapia (Oreochromis niloticus). Aquaculture 2016, 454, 125–129. [Google Scholar] [CrossRef]
  64. Jia, P.-P.; Hu, Y.-H.; Chi, H.; Sun, B.-G.; Yu, W.-G.; Sun, L. Comparative study of four flagellins of Vibrio anguillarum: Vaccine potential and adjuvanticity. Fish Shellfish Immunol. 2013, 34, 514–520. [Google Scholar] [CrossRef]
  65. Yang, H.; Chen, J.; Yang, G.; Zhang, X.-H.; Liu, R.; Xue, X. Protection of Japanese flounder (Paralichthys olivaceus) against Vibrio anguillarum with a DNA vaccine containing the mutated zinc-metalloprotease gene. Vaccine 2009, 27, 2150–2155. [Google Scholar] [CrossRef]
  66. Li, H.; Xing, J.; Tang, X.; Sheng, X.; Chi, H.; Zhan, W. Two bicistronic DNA vaccines against Vibrio anguillarum and the immune effects on flounder Paralichthys olivaceus. J. Oceanol. Limnol. 2022, 40, 786–804. [Google Scholar] [CrossRef]
  67. Xing, J.; Xu, H.; Tang, X.; Sheng, X.; Zhan, W. A DNA Vaccine Encoding the VAA Gene of Vibrio anguillarum Induces a Protective Immune Response in Flounder. Front. Immunol. 2019, 10, 499. [Google Scholar] [CrossRef] [Green Version]
  68. Zhou, X.; Xing, J.; Tang, X.; Zhan, W. Evaluation of bivalent vaccines candidates among VAA, OmpK and OmpR from Vibrio anguillarum in flounder (Paralichthys olivaceus). Dev. Comp. Immunol. 2018, 85, 1–9. [Google Scholar] [CrossRef]
  69. Xing, J.; Zhang, Z.; Luo, K.; Tang, X.; Sheng, X.; Zhan, W. T and B lymphocytes immune responses in flounder (Paralichthys olivaceus) induced by two forms of outer membrane protein K from Vibrio anguillarum: Subunit vaccine and DNA vaccine. Mol. Immunol. 2019, 118, 40–51. [Google Scholar] [CrossRef]
  70. Li, J.; Tang, L.; Li, S.; Li, G.; Mo, Z. The efficacy and side-effects of oil-based adjuvants emulsified Vibrio anguillarum bivalent inactivated vaccine in turbot (Scophthalmus maximus) under production mode. Aquaculture 2020, 524, 735259. [Google Scholar] [CrossRef]
  71. Liu, X.; Zhang, H.; Gao, Y.; Zhang, Y.; Wu, H.; Zhang, Y. Efficacy of chitosan oligosaccharide as aquatic adjuvant administrated with a formalin-inactivated Vibrio anguillarum vaccine. Fish Shellfish Immunol. 2015, 47, 855–860. [Google Scholar] [CrossRef]
  72. Sun, X.; Jin, P.; Liu, Q.; Wang, Q.; Zhang, Y.; Liu, X. A CpG-riched plasmid as vaccine adjuvant reduce antigen dose of an inactivated Vibrio anguillarum vaccine in turbot (Scophthalmus maximus L.). Fish Shellfish Immunol. 2020, 98, 312–317. [Google Scholar] [CrossRef]
  73. Torres-Corral, Y.; Girons, A.; González-Barreiro, O.; Seoane, R.; Riaza, A.; Santos, Y. Effect of Bivalent Vaccines against Vibrio anguillarum and Aeromonas salmonicida Subspecie achromogenes on Health and Survival of Turbot. Vaccines 2021, 9, 906. [Google Scholar] [CrossRef]
  74. Liu, W.; Xing, J.; Tang, X.; Sheng, X.; Chi, H.; Zhan, W. Characterization of Co-Stimulatory Ligand CD80/86 and Its Effect as a Molecular Adjuvant on DNA Vaccine Against Vibrio anguillarum in Flounder (Paralichthys olivaceus). Front. Immunol. 2022, 13, 881753. [Google Scholar] [CrossRef]
  75. Xu, H.; Xing, J.; Tang, X.; Sheng, X.; Zhan, W. The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus). Dev. Comp. Immunol. 2019, 103, 103492. [Google Scholar] [CrossRef]
  76. Lee, S.H.; Beck, B.R.; Hwang, S.-H.; Song, S.K. Feeding olive flounder (Paralichthys olivaceus) with Lactococcus lactis BFE920 expressing the fusion antigen of Vibrio OmpK and FlaB provides protection against multiple Vibrio pathogens: A universal vaccine effect. Fish Shellfish Immunol. 2021, 114, 253–262. [Google Scholar] [CrossRef]
  77. Chakraborty, S.; Cao, T.; Hossain, A.; Gnanagobal, H.; Vasquez, I.; Boyce, D.; Santander, J. Vibrogen-2 vaccine trial in lumpfish (Cyclopterus lumpus) against Vibrio anguillarum. J. Fish Dis. 2019, 42, 1057–1064. [Google Scholar] [CrossRef]
  78. Wang, C.; Hu, Y.-H.; Sun, B.-G.; Chi, H.; Li, J.; Sun, L. Environmental isolates P1SW and V3SW as a bivalent vaccine induce effective cross-protection against Edwardsiella tarda and Vibrio anguillarum. Dis. Aquat. Org. 2013, 103, 45–53. [Google Scholar] [CrossRef]
  79. Yu, L.; Hu, Y.; Sun, B.; Sun, L. C312M: An attenuated Vibrio anguillarum strain that induces immunoprotection as an oral and immersion vaccine. Dis. Aquat. Org. 2012, 102, 33–42. [Google Scholar] [CrossRef] [Green Version]
  80. Baliga, P.; Shekar, M.; Venugopal, M.N. Potential Outer Membrane Protein Candidates for Vaccine Development Against the Pathogen Vibrio anguillarum: A Reverse Vaccinology Based Identification. Curr. Microbiol. 2017, 75, 368–377. [Google Scholar] [CrossRef]
  81. Vieira, V.V.; Teixeira, L.F.; Vicente, A.C.; Momen, H.; Salles, C.A. Differentiation of environmental and clinical isolates of Vibrio mimicus from Vibrio cholerae by multilocus enzyme electrophoresis. Appl. Environ. Microbiol. 2001, 67, 2360–2364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Zhang, X.; Li, Y.-W.; Mo, Z.-Q.; Luo, X.-C.; Sun, H.-Y.; Liu, P.; Li, A.-X.; Zhou, S.-M.; Dan, X.-M. Outbreak of a novel disease associated with Vibrio mimicus infection in fresh water cultured yellow catfish, Pelteobagrus fulvidraco. Aquaculture 2014, 432, 119–124. [Google Scholar] [CrossRef]
  83. Geng, Y.; Liu, D.; Han, S.; Zhou, Y.; Wang, K.; Huang, X.; Chen, D.; Peng, X.; Lai, W. Outbreaks of vibriosis associated with Vibrio mimicus in freshwater catfish in China. Aquaculture 2014, 433, 82–84. [Google Scholar] [CrossRef]
  84. Cao, J.; Zhu, X.-C.; Liu, X.-Y.; Yuan, K.; Zhang, J.-J.; Gao, H.-H.; Li, J.-N. An oral double-targeted DNA vaccine induces systemic and intestinal mucosal immune responses and confers high protection against Vibrio mimicus in grass carps. Aquaculture 2019, 504, 248–259. [Google Scholar] [CrossRef]
  85. Cao, J.; Huang, A.-L.; Zhu, X.-C.; Li, L.; Li, J.-N. Construction of Vibrio mimicus ghosts as a novel inactivated vaccine candidate and its protective efficacy against ascites disease in grass carps (Ctenopharyngodon idella). Aquaculture 2018, 485, 147–153. [Google Scholar] [CrossRef]
  86. Zhang, Y.-Q.; Zhang, T.-T.; Li, J.-N.; Liu, X.-L.; Li, L. Design and evaluation of a tandemly arranged outer membrane protein U (OmpU) multi-epitope as a potential vaccine antigen against Vibrio mimicus in grass carps (Ctenopharyngodon idella). Vet. Immunol. Immunopathol. 2014, 160, 61–69. [Google Scholar] [CrossRef]
  87. Li, J.-N.; Zhao, Y.-T.; Cao, S.-L.; Wang, H.; Zhang, J.-J. Integrated transcriptomic and proteomic analyses of grass carp intestines after vaccination with a double-targeted DNA vaccine of Vibrio mimicus. Fish Shellfish Immunol. 2019, 98, 641–652. [Google Scholar] [CrossRef]
  88. Cao, S.-L.; Guo, J.-J.; Zhao, W.-P.; Yang, W.-F.; Zhang, S.-L.; Tao, H.-Z.; Li, J.-N. Impacts of oral Vibrio mimicus double-targeted DNA vaccine on the gut microbiota in grass carps (Ctenopharyngodon idella) and correlations with intestinal mucosa innate immunity. Aquaculture 2020, 533, 736201. [Google Scholar] [CrossRef]
  89. Yu, Z.; Geng, Y.; Wang, K.; Chen, D.; Huang, X.; Ou, Y.; Peng, G. Complete genome sequence of Vibrio mimicus strain SCCF01 with potential application in fish vaccine development. Virulence 2017, 8, 1028–1030. [Google Scholar] [CrossRef] [Green Version]
  90. Yu, Z.; Wang, E.; Geng, Y.; Wang, K.; Chen, D.; Huang, X.; Ouyang, P.; Zuo, Z.; He, C.; Tang, L.; et al. Multiplex genome editing by natural transformation in Vibrio mimicus with potential application in attenuated vaccine development. Fish Shellfish Immunol. 2019, 92, 377–383. [Google Scholar] [CrossRef]
  91. Deng, Y.; Chen, C.; Zhao, Z.; Huang, X.; Yang, Y.; Ding, X. Complete Genome Sequence of Vibrio alginolyticus ZJ-T. Genome Announc. 2016, 4, e00912-16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. El-Gohary, M.; El Gamal, A.M.; Atia, A.; El-Dakrour, M. Treatment Trial of Nile Tilapia (Oreochromis niloticus) Experimentally Infected with Vibrio alginolyticus Isolated from Sea bass (Dicentrarchus labrax). Pak. J. Biol. Sci. 2020, 23, 1591–1600. [Google Scholar] [CrossRef] [PubMed]
  93. Oh, E.-G.; Son, K.-T.; Yu, H.; Lee, T.-S.; Lee, H.-J.; Shin, S.; Kwon, J.-Y.; Park, K.; Kim, J. Antimicrobial Resistance of Vibrio parahaemolyticus and Vibrio alginolyticus Strains Isolated from Farmed Fish in Korea from 2005 through 2007. J. Food Prot. 2011, 74, 380–386. [Google Scholar] [CrossRef] [PubMed]
  94. Kang, C.-H.; Shin, Y.; Jang, S.; Jung, Y.; So, J.-S. Antimicrobial susceptibility of Vibrio alginolyticus isolated from oyster in Korea. Environ. Sci. Pollut. Res. 2016, 23, 21106–21112. [Google Scholar] [CrossRef] [PubMed]
  95. Supardy, N.A.; Ibrahim, D.; Nor, S.R.M.; Noordin, W.N. Bioactive Compounds of Pseudoalteromonas sp. IBRL PD4.8 Inhibit Growth of Fouling Bacteria and Attenuate Biofilms of Vibrio alginolyticus FB3. Pol. J. Microbiol. 2019, 68, 21–33. [Google Scholar] [CrossRef] [Green Version]
  96. Sasikala, D.; Srinivasan, P. Characterization of potential lytic bacteriophage against Vibrio alginolyticus and its therapeutic implications on biofilm dispersal. Microb. Pathog. 2016, 101, 24–35. [Google Scholar] [CrossRef]
  97. Kokkari, C.; Sarropoulou, E.; Bastías, R.; Mandalakis, M.; Katharios, P. Isolation and characterization of a novel bacteriophage infecting Vibrio alginolyticus. Arch. Microbiol. 2018, 200, 707–718. [Google Scholar] [CrossRef] [PubMed]
  98. Chen, L.; Liu, Q.; Fan, J.; Yan, T.; Zhang, H.; Yang, J.; Deng, D.; Liu, C.; Wei, T.; Ma, Y. Characterization and Genomic Analysis of ValSw3-3, a New Siphoviridae Bacteriophage Infecting Vibrio alginolyticus. J. Virol. 2020, 94, e00066-20. [Google Scholar] [CrossRef] [Green Version]
  99. Li, X.; Zhang, C.; Wei, F.; Yu, F.; Zhao, Z. Bactericidal activity of a holin-endolysin system derived from Vibrio alginolyticus phage HH109. Microb. Pathog. 2021, 159, 105135. [Google Scholar] [CrossRef]
  100. Matamp, N.; Bhat, S.G. Phage Endolysins as Potential Antimicrobials against Multidrug Resistant Vibrio alginolyticus and Vibrio parahaemolyticus: Current Status of Research and Challenges Ahead. Microorganisms 2019, 7, 84. [Google Scholar] [CrossRef]
  101. Yang, M.-J.; Xu, D.; Yang, D.-X.; Li, L.; Peng, X.-X.; Chen, Z.-G.; Li, H. Malate enhances survival of zebrafish against Vibrio alginolyticus infection in the same manner as taurine. Virulence 2020, 11, 349–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Lim, K.C.; Yusoff, F.M.; Shariff, M.; Kamarudin, M.S. Dietary astaxanthin augments disease resistance of Asian seabass, Lates calcarifer (Bloch, 1790), against Vibrio alginolyticus infection. Fish Shellfish Immunol. 2021, 114, 90–101. [Google Scholar] [CrossRef] [PubMed]
  103. Setiaji, J.; Feliatra, F.; Teruna, H.Y.; Lukistyowati, I.; Suharman, I.; Muchlisin, Z.A.; Johan, T.I. Antibacterial activity in secondary metabolite extracts of heterotrophic bacteria against Vibrio alginolyticus, Aeromonas hydrophila, and Pseudomonas aeruginosa. F1000Research 2020, 9, 1491. [Google Scholar] [CrossRef] [PubMed]
  104. Liu, H.; Wang, Q.; Liu, Q.; Cao, X.; Shi, C.; Zhang, Y. Roles of Hfq in the stress adaptation and virulence in fish pathogen Vibrio alginolyticus and its potential application as a target for live attenuated vaccine. Appl. Microbiol. Biotechnol. 2011, 91, 353–364. [Google Scholar] [CrossRef]
  105. Chen, Y.; Cai, S.; Jian, J. Protection against Vibrio alginolyticus in pearl gentian grouper (female symbol Epinephelus fuscoguttatus × male symbol Epinephelus lanceolatu) immunized with an acfA-deletion live attenuated vaccine. Fish Shellfish Immunol. 2019, 86, 875–881. [Google Scholar] [CrossRef] [PubMed]
  106. Pang, H.; Qiu, M.; Zhao, J.; Hoare, R.; Monaghan, S.J.; Song, D.; Chang, Y.; Jian, J. Construction of a Vibrio alginolyticus hopPmaJ (hop) mutant and evaluation of its potential as a live attenuated vaccine in orange-spotted grouper (Epinephelus coioides). Fish Shellfish Immunol. 2018, 76, 93–100. [Google Scholar] [CrossRef] [Green Version]
  107. Pang, H.; Chang, Y.; Zheng, H.; Tan, H.; Zhou, S.; Zeng, F.; Hoare, R.; Monaghan, S.J.; Wang, N.; Ding, Y. A live attenuated strain of HY9901ΔvscB provides protection against Vibrio alginolyticus in pearl gentian grouper (♀Epinephelus fuscoguttatus × ♂Epinephelus lanceolatu). Aquaculture 2022, 546, 737353. [Google Scholar] [CrossRef]
  108. Chen, Y.; Wu, F.; Wang, Z.; Tang, J.; Cai, S.; Jian, J. Construction and evaluation of Vibrio alginolyticus ΔclpP mutant, as a safe live attenuated vibriosis vaccine. Fish Shellfish Immunol. 2020, 98, 917–922. [Google Scholar] [CrossRef]
  109. Zhou, S.; Tu, X.; Pang, H.; Hoare, R.; Monaghan, S.J.; Luo, J.; Jian, J. A T3SS Regulator Mutant of Vibrio alginolyticus Affects Antibiotic Susceptibilities and Provides Significant Protection to Danio rerio as a Live Attenuated Vaccine. Front. Cell. Infect. Microbiol. 2020, 10, 183. [Google Scholar] [CrossRef]
  110. Yang, J.; Yang, X.-L.; Su, Y.-B.; Peng, X.-X.; Li, H. Activation of the TCA Cycle to Provide Immune Protection in Zebrafish Immunized by High Magnesium-Prepared Vibrio alginolyticus Vaccine. Front. Immunol. 2021, 12, 739591. [Google Scholar] [CrossRef]
  111. Cai, S.H.; Lu, Y.S.; Wu, Z.H.; Jian, J.C. Cloning, expression of Vibrio alginolyticus outer membrane protein-OmpU gene and its potential application as vaccine in crimson snapper, Lutjanus erythropterus Bloch. J. Fish Dis. 2013, 36, 695–702. [Google Scholar] [CrossRef] [PubMed]
  112. Nehlah, R.; Firdaus-Nawi, M.; Nik-Haiha, N.Y.; Karim, M.; Zamri-Saad, M.; Ina-Salwany, M.Y. Recombinant vaccine protects juvenile hybrid grouper, Epinephelus fuscoguttatus × Epinephelus lanceolatus, against infection by Vibrio alginolyticus. Aquac. Int. 2017, 25, 2047–2059. [Google Scholar] [CrossRef]
  113. Chen, C.; Kang, C.; Rong, N.; Wu, N.; Chen, C.; Wu, S.; Zhang, X.; Liu, X. Evaluation of Immunogenicity, Protective Immunity on Aquaculture Pathogenic Vibrio and Fermentation of Vibrio alginolyticus Flagellin FlaC Protein. Iran. J. Biotechnol. 2019, 17, e2628-42. [Google Scholar]
  114. Cheng, Z.-X.; Chu, X.; Wang, S.-N.; Peng, X.-X.; Li, H. Six genes of ompA family shuffling for development of polyvalent vaccines against Vibrio alginolyticus and Edwardsiella tarda. Fish Shellfish Immunol. 2018, 75, 308–315. [Google Scholar] [CrossRef] [PubMed]
  115. Liang, H.; Wu, Z.-H.; Jian, J.-C.; Huang, Y. Protection of red snapper (Lutjanus sanguineus) against Vibrio alginolyticus with a DNA vaccine containing flagellin flaA gene. Lett. Appl. Microbiol. 2010, 52, 156–161. [Google Scholar] [CrossRef]
  116. Cai, S.-H.; Lu, Y.-S.; Jian, J.-C.; Wang, B.; Huang, Y.-C.; Tang, J.-F.; Ding, Y.; Wu, Z.-H. Protection against Vibrio alginolyticus in crimson snapper Lutjanus erythropterus immunized with a DNA vaccine containing the ompW gene. Dis. Aquat. Org. 2013, 106, 39–47. [Google Scholar] [CrossRef] [Green Version]
  117. Peng, Y.-M.; Tao, J.-J.; Kuang, S.-F.; Jiang, M.; Peng, X.-X.; Li, H. Identification of Polyvalent Vaccine Candidates From Extracellular Secretory Proteins in Vibrio alginolyticus. Front. Immunol. 2021, 12, 736360. [Google Scholar] [CrossRef]
  118. Cao, J.; Zhang, J.; Ma, L.; Li, L.; Zhang, W.; Li, J. Identification of fish source Vibrio alginolyticus and evaluation of its bacterial ghosts vaccine immune effects. Microbiologyopen 2018, 7, e00576. [Google Scholar] [CrossRef] [Green Version]
  119. Ji, Q.; Wang, S.; Ma, J.; Liu, Q. A review: Progress in the development of fish Vibrio spp. vaccines. Immunol. Lett. 2020, 226, 46–54. [Google Scholar] [CrossRef]
  120. Dadar, M.; Dhama, K.; Vakharia, V.N.; Hoseinifar, S.H.; Karthik, K.; Tiwari, R.; Khandia, R.; Munjal, A.; Salgado-Miranda, C.; Joshi, S.K. Advances in Aquaculture Vaccines Against Fish Pathogens: Global Status and Current Trends. Rev. Fish. Sci. Aquac. 2016, 25, 184–217. [Google Scholar] [CrossRef]
Figure 1. Strategies for prevention and control of vibriosis in Asian fish culture mentioned in this review.
Figure 1. Strategies for prevention and control of vibriosis in Asian fish culture mentioned in this review.
Vaccines 11 00098 g001
Table 2. Control and prevention strategies of V. vulnificus. NR: Not Relevant.
Table 2. Control and prevention strategies of V. vulnificus. NR: Not Relevant.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. vulnificusVaccinesInactivatedTilapia
(Sex reversed hybrid)
Atypical V. vulnificus
(Formalin killed cells)
Injection (IP)[34]
E. coioidesVh + Vv + Va inactive vaccine and ISKNV
whole cell inactive vaccine
Injection (IP)[16]
SubunitJapanese eelExpressed OmpU of
V. vulnificus
Injection (IP)[35]
MultivalentJapanese eelRecombinant Omp containing both OmpA and OmpUInjection (IP)[36]
European eelTrivalent outer membrane protein (OmpⅡ-U-A)Injection (IP)[37]
Table 3. Control and prevention strategies of V. parahaemolyticus. NR: Not Relevant.
Table 3. Control and prevention strategies of V. parahaemolyticus. NR: Not Relevant.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. parahaemolyticusVaccinesInactivatedTiger grouperVaksin polivalen Vibrio (formalin killed cells)Injection,
Bath
[43]
RecombinantJuvenile
sea bass
Expressed r-OmpK
of Vibrio
Injection (IP)[27]
Table 4. Control and prevention strategies of V. cholerae. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
Table 4. Control and prevention strategies of V. cholerae. NR: Not Relevant, None: the method has not been tested in vivo or relevant data has not been found.
PathogenPrevention and
Control Technology
Concrete Measure/
Vaccine Type
HostRoute of InfectionRef.
V. choleraeAntibioticsNeomycin, DoxycyclineBluegill sunfishInjection (IP)[49]
Edible antibodyAnti-non-O1 V. cholerae
egg yolk powder
CarpInjection[51]
VaccinesNoneNoneNoneNone
Table 6. Control and prevention strategies of V. mimicus. NR: Not Relevant.
Table 6. Control and prevention strategies of V. mimicus. NR: Not Relevant.
PathogenPrevention and Control TechnologyConcrete Measure/
Vaccine Type
HostVaccine Antigen ComponentsRoute of InfectionRef.
V. mimicusAntibioticsFlorfenicol, Gentamicin, LomefloxacinSouthern catfishNRInjection (IP)[83]
VaccinesDNAGrass carpBGS and ICLPInjection (IP),
Oral
[84]
AttenuatedYellow catfishV. mimicus SCCF01
(attenuated)
Bath[89]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Xu, K.; Wang, Y.; Yang, W.; Cai, H.; Zhang, Y.; Huang, L. Strategies for Prevention and Control of Vibriosis in Asian Fish Culture. Vaccines 2023, 11, 98. https://doi.org/10.3390/vaccines11010098

AMA Style

Xu K, Wang Y, Yang W, Cai H, Zhang Y, Huang L. Strategies for Prevention and Control of Vibriosis in Asian Fish Culture. Vaccines. 2023; 11(1):98. https://doi.org/10.3390/vaccines11010098

Chicago/Turabian Style

Xu, Kangping, Yushu Wang, Wangxiaohan Yang, Hongyan Cai, Youyu Zhang, and Lixing Huang. 2023. "Strategies for Prevention and Control of Vibriosis in Asian Fish Culture" Vaccines 11, no. 1: 98. https://doi.org/10.3390/vaccines11010098

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop